Video

Dr. Desai on Phase I Study of Entrectinib in Solid Tumors

Ami Vijay Desai, MD, assistant professor of Pediatrics, University of Chicago Comer Children's Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors.

Ami Vijay Desai, MD, assistant professor of pediatrics, University of Chicago Comer Children’s Hospital, discusses the design of a phase I study testing entrectinib in patients with solid tumors. She presented these findings at the 2018 ASCO Annual Meeting.

The trial followed a 3+3 dose escalation format and investigated 4 dose levels, Desai says. Researchers were able to escalate to the fourth dose level—at the third level, there was 1 dose-limiting toxicity of increased creatinine for >7 days. At the fourth level, there were 3 dose-limiting toxicities across 2 patients. Desai says these toxicities were reversible on discontinuation of drug.

Phase I data suggest the recommended dose level of entrectinib for pediatric patients is 550 mg/m2, according to Desai.

Related Videos
YI LIN, MD, PHD
Dr Fakih on the FDA Approval of Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC
Al Malki
Ian Krop MD, PhD
Timothy S. Fenske, MD, MS
Ignacio Garrido-Laguna, MD, PhD, MBA
Marwan G. Fakih, MD
Dr Alderuccio on Loncastuximab Tesirine With Rituximab in R/R Follicular Lymphoma
Dr Cascone on Evaluating Neoadjuvant Durvalumab-Based Regimens in Resectable NSCLC
Werutsky